A study efficacy of pyridoxine in early-onset idiopathic intractable seizures in pediatric patient at tertiary health care center

Background: Pyridoxine is used for management of seizure disorder in three settings viz., seizures that respond to pyridoxine and require life-long supplementation with therapeutic doses of pyridoxine, pyridoxine dependent seizures Aims and Objectives: study Efficacy of Pyridoxine in Early-Onset Idiopathic Intractable Seizures in pediatric patient at tertiary health care center. Methodology: This was a cross-sectional study carried out in the patients of Early-Onset Idiopathic Intractable Seizures in pediatric patient during the one year period i.e. June 2017 to June 2018, there were 64 pediatric patients with Idiopathic Intractable Seizures were enrolled for the study. All details of the patients like Age, sex etc. was noted. All the patients were undergone EEG testing. Out of 64 patients Group A received 30 mg/kg/day pyridoxine with 4 mg/kg/day of oral prednisolone Group B received 4 mg/kg/day of oral prednisolone and 14, 15 randomly. The outcome of patients like episodes of seizure etc. was noted after 1 month of treatment. The statistical analysis was done by Chi-square test and analyzed by SPSS 19 version software. Result: In our study the average age in both the group was comparable with each other i.e. 3 ±1.21Yrs. and 3.52±1.31 Yrs. (p>0.05, t=1.12,df=62). The ratio of Male and Female was 2.9: 1 and 1.90: 1 was comparable with each other (X2=0.29, df=1,p>0.05). Complete seizure freedom was found in 34.38% and 9.38%; >50% seizure reduction but not complete cessation in 40.63% and 28.13%; <50% seizure reduction in 25.00% and 62.50% respectively in Group A and Group B which was statistically significant (X2=10.44, df=2,p<0.005). EEG findings Normal in 37.50% and 12.50%, Decreased Epileptiform discharges in 46.88% and 31.25%, Persistent Epileptiform discharges in 15.63% and 56.25% respectively in Group A and Group B this observed difference was statistically significant (X2=12.35, df=2,p<0.002) Conclusion: It can be concluded from our study that the patients who received the pyridoxine treatment improved much as compared to not received so the role of pyridoxine in the treatment of intractable seizure should not be underestimated. Key Word: Pyridoxine, Early-Onset Idiopathic Intractable Seizures, EEG Address for Correspondence: Dr. Jagadish N Bhadbhade, Assistant Professor, Department of Paediatrics, Vedaantaa Institute of Medical Sciences, At Saswand, Dhundalwadi, Talk. Dahanu, Dist. Palghar401602, Maharashtra, INDIA. Email: jagadish_bhadbhade@yahoo.co.in Received Date: 29/01/2019 Revised Date: 19/02/2019 Accepted Date: 14/03/2019 DOI: https://doi.org/10.26611/1014937 INTRODUCTION Pyridoxine is used for management of seizure disorder in three settings viz., seizures that respond to pyridoxine and require life-long supplementation with therapeutic doses of pyridoxine, pyridoxine dependent seizures (PDS, MIM 266100); early-onset seizures responsive to pyridoxine but not requiring life-long pyridoxine supplementation, pyridoxine-responsive seizures (PRS); and, high-dose pyridoxine for the treatment of major seizure disorders of young children e.g., West syndrome1. It has been suggested that pyridoxine dependency is often underdiagnosed, both because of occasional atypical presentation2, and infrequent use of pyridoxine in Access this article online Quick Response Code: Website: